Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Changes in the Management Board of Swedbank Estonia

The Council of Swedbank Estonia has decided to appoint Olavi Lepp as permanent CEO, and Anna Kõuts as permanent CFO of Swedbank Estonia. Following a Council decision, three members of the Management Board will leave their positions and the bank.“The change in leadership will take Swedbank Estonia forward. Olavi Lepp and Anna Kõuts are both experienced banking leaders and have contributed strongly to the development of Swedbank”, says Björn Elfstrand, Council Chair of Swedbank Estonia. “Our commitment to develop Swedbank in Estonia with our customers and society in focus is strong and

Össur hf: Transactions in relation to share buyback program

Announcement no. 57/2019 30 September 2019On 10 September 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 53/2019. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 December 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under

Moberg Pharma proposes to pay the shareholders SEK 46.50 per ordinary share and repays the MOB-015 loan

STOCKHOLM, September 30th, 2019. As previously communicated, Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company"), intends to propose the Annual General Meeting for the abbreviated financial year 2019 to resolve on a payment to the shareholders through redemption of shares. The Board of Directors has now set the proposed redemption amount to SEK 46.50 per share. Moberg Pharma also announces that the Company intends to repay the loan of USD 2.5 million that the Company incurred from the purchaser in connection with the divestment of the Company's OTC-business last spring.Moberg Pharma

Kai Wärn to become Chairman of the Board of Electrolux Professional AB

The Board of Directors of AB Electrolux (“Electrolux”) today announced the appointment of Kai Wärn as Chairman of the Board of Directors of Electrolux Professional AB (“Electrolux Professional”), the company intended to be distributed to AB Electrolux shareholders in 2020.As previously announced, Electrolux Professional is intended to be distributed to the shareholders of Electrolux and listed during the first half of 2020, subject to shareholder approval. As a step in the preparations for the distribution and intended listing, Electrolux has appointed Kai Wärn as Chairman of the Board of

SRV Group Plc - Managers' transactions

SRV GROUP PLC    MANAGERS' TRANSACTIONS    30 SEPTEMBER 2019    19.00 EET SRV Group Plc - Managers' transactions Notification under the EU Market Abuse Regulation, article 19 Person subject to the notification requirementName: Havu Capital Oy Legal PersonPosition: Closely associated person Person discharging managerial responsibilities in issuerName: Kokkila TimoPosition: Member of the Board/Deputy member      Initial

SRV Group Plc: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10

SRV GROUP PLC                      STOCK EXCHANGE RELEASE             30 SEPTEMBER 2019    18.50 EET SRV Group Plc: Notice pursuant to the Finnish Securities Market Act, Chapter 9, Section 10 SRV Group Plc has received an announcement from Timo Tapani Kokkila on 30 September 2019, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcementTimo Tapani Kokkila’s direct holding in SRV Group Plc ‘s shares decreased below 5 per cent and his indirect holding through Havu Capital Oy, a company controlled by him, exceeded over 10 per cent of the

OrganoClick explores the conditions for carrying out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, SOUTH KOREA OR THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR SUBJECT TO LEGAL RESTRICTIONS. PLEASE SEE IMPORTANT INFORMATION BELOW. OrganoClick AB (publ) (”OrganoClick” or ”the Company”) has engaged ABG Sundal Collier to explore the conditions for carrying out a directed share issue corresponding to a value of circa SEK 65 million through an

Change in number of shares and votes in Hembla

The number of shares of series B and votes in Hembla AB (publ) has changed during the month of September as a result of the exercise of 97,000 warrants, in exchange for 100,589 shares of series B, within the framework of the company’s incentive program which was adopted at the annual general meeting 2016. As of the last trading day of the month there were in total 92,924,306 shares in the company, whereof 6,136,989 shares of series A and 86,787,317 shares of series B, and 117,472,262 votes in the company. For more information, please contactSvein Erik Lilleland, CEO, Phone: +46 (0) 8

Number of shares and votes in Samhällsbyggnadsbolaget i Norden AB (publ)

Pursuant to the Swedish Financial Instruments Trading Act, Swedish companies whose shares are listed on a regulated market and that increase or reduce the total number of shares or votes in the company must disclose such changes on the last trading day the same month. As of 30 September 2019, there are 832,577,974 shares and 272,237,539 votes in Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) distributed as follows: Common shares class A: 209,977,491 shares and 209,977,491 votes Common shares class B: 546,071,540 shares and 54,607,154 votes Common shares class D: 76,498,230

EAB GROUP PLC: ACQUISITION OF OWN SHARES 30.09.2019

EAB GROUP PLC  NOTIFICATION 30.09.2019 at 18:30 EAB GROUP PLC: ACQUISITION OF OWN SHARES 30.09.2019 Date 30.09.2019Exchange transaction BuyShare class EABAmount 190 Average price/share 2.8400 EUR  Highest price/share 2.8400 EUR Lowest price/share 2.8400 EUR Total price  539.60 EUR  The shares held by EAB Group Plc on 30.09.2019: EAB 1,865 On behalf of EAB Group Plc Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Mikko Virtanen For more information, please

United Bankers Corporation: Acquisition of Own Shares 30.09.2019

United Bankers Corporation NOTIFICATION 30.09.2019 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 30.09.2019 Date 30.09.2019Exchange transaction BuyShare class UNIAVAmount 125Average price/share 8.4600 EURHighest price/share 8.7000 EURLowest price/share 8.4000 EURTotal price 1,057.50 EUR The shares held by United Bankers Corporation on 30.09.2019: UNIAV 26,827 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ) Antti Salakka

DNO North Sea plc: First Half 2019 Interim Results

Oslo, 30 September 2019 - DNO North Sea plc, a wholly-owned subsidiary of DNO ASA effective as from 21 March 2019 (previously named Faroe Petroleum plc), today releases its First Half 2019 Interim Results. The report is attached as downloadable file and also available at DNO's website at www.dno.no. http://www.rns-pdf.londonstockexchange.com/rns/2068O_1-2019-9-30.pdf -- For further information, please contact: Media: media@dno.noInvestors: investor.relations@dno.no -- This information is subject to the disclosure requirements pursuant to section 3.4.6 of the Nordic

PolarCool AB (publ) has decided to initiate development of a mobile application (APP)

At the latest board meeting, held on September 26, 2019, PolarCool AB (publ) decided to begin the development of mobile application (APP) to be used primarily as support for the athlete during the rehabilitation amidst a mild traumatic brain injury (mTBI) and concussion-related diseases. The APP development is intended to be conducted in collaboration with an IT partner. PolarCool AB (publ) currently estimates that the APP development will not affect the company's revenues for 2019 and 2020. The cost of developing the APP cannot be assessed today and is entirely dependent on the contract

Lynparza more than doubled the time without

30 September 2019 15:30 BST Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progression or death by 51% in men with homologous recombination repair (HRR) gene mutations First positive Phase III trial testing a targeted treatmentin biomarker-selected prostate cancer patients AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today presented

#19-1065 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Rejlers acquisition from Neste completed

Rejlers has today completed the acquisition of strategically important businesses from Neste Engineering Solutions that was announced on 19 June this year.The acquired entities have 330 employees in Finland, Sweden and the United Arab Emirates (Abu Dhabi) and strengthens Rejlers within the energy sector. Rejlers acquires process industry expertise, especially within the hydrocarbon- and bioindustry, where the acquired businesses have decades of experiences from assignments across all phases of the life cycle. In connection with the acquisition, the parties entered into a five year strategic

Getinge continues to focus on advancing patient care in cardiovascular and cardiothoracic procedures

Getinge announces its commitment to the European Association for Cardio-Thoracic Surgery (EACTS) meeting, supporting the advanced education in the field of cardiac, thoracic and vascular interventions. For more than 50 years, coronary artery bypass graft (CABG) surgery has been the standard of care for revascularization of patients with coronary artery disease¹. Today’s CABG patient has a higher risk profile due to multiple co-morbidities, which contributes to an increase in surgical complexity, perioperative complications and cost². These patients present new challenges and have

Quant extends maintenance contract with Norilsk Nickel

Quant has extended a Total Maintenance Partnership agreement with long-time customer Norilsk Nickel Harjavalta Oy. In connection with the extension of the maintenance contract, a financial institute will take over a spare parts inventory related to the site on behalf of Norilsk Nickel Harjavalta Oy, resulting in a positive cashflow effect of EUR 7.2 million for Quant Finland Oy.Norilsk Nickel Harjavalta Oy and Quant Finland Oy have agreed to extend the current Total Maintenance Partnership agreement. The contract was originally entered in 1999 and covers the total maintenance on the Norilsk

Change in the number of shares and votes in Projektengagemang following conversion

The number of shares and votes in Projektengagemang Sweden AB (publ) has changed due to conversion of 16 200 class A shares to 16 200 class B shares.Pursuant to the articles of association of Projektengagemang, a holder of a class A share is entitled to request that the share is converted into a class B share. In September 2019, 16 200 class A shares have been converted into 16 200 class B shares, at the request of shareholders. After the conversion, as of 09/30 2019, the total number of shares and votes in Projektengagemang Sweden AB (publ) amounted to 24 555 677 shares and 73 390 793

Arjo announces date of 2019 Q3 report and conference call

Arjo will issue its Q3 report for 2019 on Tuesday October 22 at 13:00 CET, followed by a conference call at 14:00 CET, hosted by Joacim Lindoff, President & CEO, and Jonas Lindqvist, CFO. The previously communicated date of October 23 has been altered for practical reasons. We invite fund managers, analysts and the media to participate in the conference call. Please see details below to join the conference.  Swedish dial-in number: +46 (0)8 5065 3942UK: +44 (0)330 336 9411USA: +1 323-794-2597Participant passcode: 9981140 During the telephone conference, a presentation will be

Immunovia Announces Company On Track with Commercial Test Model Study

LUND, SWEDEN ― Immunovia AB (publ) (“Immunovia”) today announced that the Commercial Test Model Study for Immunovia’s IMMray™ PanCan-d, a blood-based test for early diagnosis of pancreatic cancer, is on track.  Following the excellent results from Immunovia’s Optimization Study for IMMray™ PanCan-d, the steps to market remain the same and includes the Commercial Test Model Study, now in full force, followed by the final Verification and Validation studies, after which the sales will commence in Q3 2020. Additionally, Immunovia reports that the company has already obtained all the fresh,

Creoptix Closes Successful Series C Financing Round to Support Further Growth

Wädenswil/Zurich, Switzerland, September 30, 2019 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced that is has raised CHF 8 million in the first closing as part of a Series C financing round. The round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation (NYSE: WAT) as well as existing private investors. Robert Schier of Swisscanto Invest has joined the board of directors. With this financing round, the company has raised more than CHF 15 million since 2013. The proceeds enable Creoptix to

Change in number of shares and votes in Gunnebo

Gunnebo AB (publ) has, as previously announced, carried out a rights issue of up to 19,112,145 ordinary shares in total. 18,984,309 ordinary shares subscribed for with the exercise of subscription rights have been registered with the Swedish Companies Registration Office in September 2019, and the number of shares and votes in Gunnebo has therefore increased as follows.Prior to the issuance of new ordinary shares, there were in total 77,050,848 shares in Gunnebo, of which 76,448,581 ordinary shares, corresponding to 76,448,581 votes, and 602,267 shares of series C, corresponding to 60,226.7

There are no items matching the current filter
There are no more items matching the current filter
Back to top